EPOCRATES INTRODUCES PRODUCTS FOR CLINICIANS IN EUROPE AND CANADA
  
International physicians and other healthcare professionals welcome local drug indexes to improve patient safety and save time
  
San Mateo, Calif., January 18th, 2006 - Epocrates Inc. announced its expansion into the global market today with the introduction of local brand and generic drug names integrated into its clinical applications. The Company's mobile solutions, including the Epocrates Rx® free drug reference and the Epocrates® Essentials premium drug, disease and diagnostic guide, now include drug name indexes for four countries - Canada, Germany, Spain and the United Kingdom.  
  
"I have been using Epocrates products for a number of years and believe they are the most useful medical software applications available. The addition of the local drug content now makes the products even more invaluable," said Dr. Michael Jorsh, Consultant/Honorary Senior Clinical Lecturer, Combined Healthcare NHS Trust and Keele University (UK). "Not a day goes by that I do not use Epocrates in my clinical practice for immediate access to information on drug dosing and interactions, disease treatment recommendations and more."  
  
An Epocrates survey, conducted prior to the launch, found that nearly 90 percent of clinicians currently using Epocrates applications in the four countries believe that using Epocrates has helped them avoid medical errors, and more than 50 percent reported avoiding at least one medical error a week. Furthermore, nearly 30 reported saving more than 30 minutes per day by using Epocrates, which often translates to more time with their patients. Epocrates anticipates that use of the new customized drug indexes will result in even greater patient safety and efficiency.
  
"With over 60,000 healthcare professionals outside of the U.S. actively using our products today, we are well on our way to becoming a global company," said Kirk Loevner, chairman and chief executive office of Epocrates. "We are committed to localizing our products to support clinicians around the world in their pursuit to provide superior patient care. We also look forward to working with international healthcare companies seeking to communicate with our growing network of clinicians."  
  
The addition of the local drug indexes is Epocrates' first step towards making its products and services even more valuable to clinicians in foreign countries. Epocrates will continue to enhance its clinical content and add services, including news alerts, medical education and market research. The Company also plans to expand into additional countries, including France and Italy , in 2006.  
  
ABOUT EPOCRATES, INC.
San Mateo, CA-based Epocrates is transforming the practice of medicine by providing innovative clinical solutions at the point of care and deploying leading-edge technologies that enable communication. The company has built a clinical network connecting nearly 500,000 healthcare professionals, including one in four U.S. physicians and one in two U.S. medical students, with the healthcare industry. Epocrates' products have shown a positive impact on patient safety, healthcare efficiency and patient satisfaction. Epocrates was recently ranked 257 in the 24th annual Inc.500 ranking of the fastest-growing private companies in the country. For more information about Epocrates, please visit  www.epocrates.com.
 

(25/1/06)